Name: Latest research reports of Ipca Laboratories Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 3
Author: Phillip Capital

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Falling Comet

1368.8000 4.40 (0.32%)

NSE May 08, 2025 12:53 PM

30.11% Gain from 52W Low

Volume: 49,536

Ipca Laboratories Ltd.

31 May 2016

1368.80

0.32%

IPCA Q4FY16 Update 31May2016

Neutral: Ipca Laboratories Ltd.

Recommendation Target

Phillip Capital

the formulations met expectations at Rs 4.98bn. Operating margin at 10.2% (vs estimated 17%)sawsequentialfallfrom16.6%inQ3,resultingin44%our/consensusmissonEBITDA atRs635mn.ThankstotaxreversalofRs190mnthatboostedcorePATtoRs377mn,which...

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.